Clincosm LogoSign in Get a demo

A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102

Sponsor
Eisai Inc. (Industry)
Overall Status
Withdrawn
CT.gov ID
NCT04109092
Collaborator
H3 Biomedicine Inc. (Industry)
0
Enrollment
9
Locations
3
Arms
31.5
Anticipated Duration (Months)
0
Patients Per Site
0
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is an open label, multicenter, phase 1/1b study to assess safety/tolerability and preliminary clinical activity of E7766 as a single agent administered intravesically in participants with NMIBC. Both intermediate risk and BCG-unresponsive NMIBC participants will be included.

Condition or Disease Intervention/Treatment Phase
Phase 1

Detailed Description

The Phase 1/1b study consist of two parts: Dose Escalation and Dose Expansion. In the Dose Escalation Part, E7766 will be administered intravesically to participants with intermediate risk NMIBC or participants with BCG unresponsive NMIBC with increased dose levels to assess safety/tolerability profile of E7766 and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of E7766. In the Dose Expansion Part, E7766 at RP2D will be administered to participants with NMIBC with or without carcinoma in situ (CIS) to confirm safety and assess preliminary clinical activity of E7766 as a single agent. Clinical activity will be evaluated by complete response (CR) rates at 3 months, 6 months, 12 months, 18 months, 24 months, and by duration of complete response (DOCR) in all participants who have achieved CR on treatment with E7766.

Study Design

Study Type:
Interventional
Actual Enrollment :
0 participants
Allocation:
Non-Randomized
Intervention Model:
Sequential Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
INtravesical Phase 1/1b Study of STING Agonist E7766 in NMIBC Including Subjects Unresponsive to BCG Therapy, INPUT-102
Actual Study Start Date :
Feb 13, 2020
Anticipated Primary Completion Date :
Sep 29, 2022
Anticipated Study Completion Date :
Sep 29, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Dose Escalation: NMIBC And BCG Unresponsive NMIBC

Drug: E7766
E7766, solution, intravesically.
Experimental: Dose Expansion: CIS With/Without Ta or T1

Drug: E7766
E7766, solution, intravesically.
Experimental: Dose Expansion: High-grade Ta or T1, Without CIS

Drug: E7766
E7766, solution, intravesically.

Outcome Measures

Primary Outcome Measures

  1. Dose Escalation Part: Number of Participants with Dose-limiting Toxicities (DLTs) [Baseline up to 6 weeks of the Induction Cycle (Cycle length is equal to [=] 6 weeks)]

    DLTs are any of the toxicities occurring during the 6 weeks of the Induction Cycle and assessed by the investigator as related to study drug. Toxicity will be evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v.5.0).

  2. Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) [Baseline up to 30 days after the last dose of study drug (approximately 42 months)]

  3. Dose Expansion Part: Complete Response Rate (CRR) at 3 Months [Up to 3 months]

  4. Dose Expansion Part: CRR at 6 Months [Up to 6 months]

  5. Dose Expansion Part: CRR at 12 Months [Up to 12 months]

  6. Dose Expansion Part: CRR at 18 Months [Up to 18 months]

  7. Dose Expansion Part: CRR at 24 Months [Up to 24 months]

Secondary Outcome Measures

  1. Dose Escalation Part: CRR at 3, 6, 12, 18 and 24 Months [At Months 3, 6, 12, 18, and 24]

  2. DOCR [From the date of first documented CR until the first documentation of confirmed disease recurrence (approximately 42 months)]

  3. Local Recurrence Free Rates [At Months 6, 12, 18, and 24]

  4. Cmax: Maximum Observed Plasma Concentration for E7766 [Dose Escalation: Induction Phase: Day 1: 0-24 hour post dose; Day 15: 0-8 hour post dose; Maintenance Phase: Cycle 1: Day :0- 8 hours post dose; Dose Expansion: Induction Phase: Day 1, Day 15: 0-8 hour post dose (Cycle length is 3 weeks)]

  5. Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for E7766 [Dose Escalation: Induction Phase: Day 1: 0-24 hour post dose; Day 15: 0-8 hour post dose; Maintenance Phase: Cycle 1: Day :0- 8 hours post dose; Dose Expansion: Induction Phase: Day 1, Day 15: 0-8 hour post dose (Cycle length is 3 weeks)]

  6. AUC: Area Under the Plasma Concentration Versus Time Curve for E7766 [Dose Escalation: Induction Phase: Day 1: 0-24 hour post dose; Day 15: 0-8 hour post dose; Maintenance Phase: Cycle 1: Day :0- 8 hours post dose; Dose Expansion: Induction Phase: Day 1, Day 15: 0-8 hour post dose (Cycle length is 3 weeks)]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

  1. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.

  2. Life expectancy greater than (>) 2 years in the view of the investigator.

  3. Participants must have biopsy proven transitional or predominantly transitional cell NMIBC.

  4. For the Dose Escalation part of the study, the following participants will be included:

  5. Both, lower and higher dose escalation cohorts:

Participants with intermediate risk NMIBC

  1. Only higher dose escalation cohorts:

Participants with BCG Unresponsive NMIBC despite prior adequate treatment. Furthermore, all participants should be indicated for radical cystectomy as the standard of care for BCG unresponsive NMIBC. Participants who are undergoing radical cystectomy as well as participants who have refused to undergo radical cystectomy will be eligible to participate in the Dose Escalation part of the study. For participants who are undergoing radical cystectomy, date of surgery should not be delayed more than 3 months after Day 1 of dosing.

For the Dose Expansion part of the study, the following participants will be included:

Participants with histologically confirmed

  1. CIS (with or without concomitant non-muscle invasive, Ta or T1 papillary disease) (Arm 1) Or

  2. Non-muscle invasive high-grade Ta or T1 papillary disease without CIS (Arm 2) that is deemed to be unresponsive to BCG therapy despite prior adequate treatment. Furthermore, participants should be indicated for radical cystectomy as the standard of care for BCG unresponsive NMIBC but have refused to undergo radical cystectomy.

Intermediate risk NMIBC: is defined as any participant with a high-grade Ta less than or equal to (<=) 3 cm or low-grade T1 tumor or with histologically confirmed multiple and/or recurrent low-grade Ta tumor with either 1 or 2 of the following 4 factors

  1. Multiple tumors

  2. Tumor >3 centimeter (cm)

  3. Early recurrence (less than [<] year)

  4. Frequent recurrences (>1 per year)

BCG Unresponsive NMIBC is defined as being at least 1 of the following:

  1. Persistent or recurrent CIS alone or with recurrent Ta/T1 (noninvasive papillary disease/tumor invades the subepithelial connective tissue) disease within 12 months of completion of adequate BCG therapy.

  2. Recurrent high-grade Ta/T1 disease within 6 months of completion of adequate BCG therapy.

  3. T1 high-grade disease at the first evaluation following an induction BCG course

Adequate BCG therapy is defined as at least 1 of the following:

  1. At least 5 of 6 doses of an initial induction course plus at least 2 of 3 doses of maintenance therapy.

  2. At least 5 of 6 doses of an initial induction course plus at least 2 of 6 doses of a second induction course.

  3. Participants must consent to repeat biopsies to allow the acquisition of fresh formalin-fixed paraffin embedded (FFPE) material (obtained within 8 weeks prior to treatment initiation with E7766)

  4. Participants must consent to repeat blood draws as indicated in the schedule of assessments.

  5. Participant must consent to providing cystectomy tumor sample in the event that cystectomy is performed following treatment with E7766.

  6. Immunosuppressive doses of systemic medications, such as steroids or absorbed topical steroids (doses >10 milligram per day (mg/d) prednisone or equivalent) must be safely discontinued at least 4 weeks before study drug administration.

  7. Participants with prior Hepatitis B or C are eligible if they have adequate liver function.

  8. Left ventricular ejection fraction (LVEF) >50 percent (%) on echocardiography or multiple gate acquisition (MUGA) scan.

  9. Adequate renal function, bone marrow function and liver function.

Exclusion Criteria:

  1. Other malignancy active within the previous 2 years except for basal or squamous cell skin cancer, or CIS of the cervix or breast that has completed curative therapy.

  2. Participants with any active autoimmune disease or a documented history of autoimmune disease, except for participants with vitiligo or resolved childhood asthma/atopy

  3. Presence of concomitant upper tract urothelial carcinoma or urothelial carcinoma within the prostatic urethra or any other regional/metastatic disease.

  4. Known human immunodeficiency virus (HIV) infection.

  5. Active infection requiring therapy

  6. Major surgery within 4 weeks before the first dose of study drug.

  7. Concurrent medical condition requiring the use of immunosuppressive medications or immunosuppressive doses of systemic medications, such as steroids or absorbed topical steroids (doses >10 mg/d prednisone or equivalent).

  8. Prolongation of corrected QT (corrected for QTc interval using Frederica's correction factors [QTcF]) interval to >480 millisecond (msec) when electrolytes balance is normal.

  9. Significant cardiovascular impairment.

  10. Use of illegal recreational drugs.

  11. Females who are breastfeeding or pregnant at Screening or Baseline (as documented by a positive beta-human chorionic gonadotropin [ß-hCG] (or human chorionic gonadotropin [hCG]) test with a minimum sensitivity of 25 International Units Per Liter (IU/L) or equivalent units of ß-hCG [or hCG]). A separate baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug.

  12. Currently enrolled in another clinical study or used any investigational drug or device within 28 days preceding Cycle 1 Day 1 (first dosing day).

Contacts and Locations

Locations

Site City State Country Postal Code
1 Banner MD Anderson Cancer Center Gilbert Arizona United States 85234
2 University of Southern California Los Angeles California United States 90033
3 UCLA Santa Monica California United States 90404
4 Mayo Clinic Jacksonville Jacksonville Florida United States 32224
5 Indiana University Indianapolis Indiana United States 46202
6 Washington University Saint Louis Missouri United States 63110
7 The Mount Sinai Hospital New York New York United States 10029
8 Cleveland Clinic Cleveland Ohio United States 44195
9 Ohio State University Columbus Ohio United States 43210

Sponsors and Collaborators

  • Eisai Inc.
  • H3 Biomedicine Inc.

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Eisai Inc.
ClinicalTrials.gov Identifier:
NCT04109092
Other Study ID Numbers:
  • E7766-G000-102
  • 2019-000161-21
First Posted:
Sep 30, 2019
Last Update Posted:
Dec 14, 2020
Last Verified:
Jul 1, 2020
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
Yes
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Eisai Inc.
E7766
Non-Muscle Invasive Bladder Cancer
Intravesical administration
Ta or T1 Papillary Disease
Stimulator of Interferon Genes Agonist
Carcinoma in situ
BCG Unresponsive
Additional relevant MeSH terms:
Urinary Bladder Neoplasms

Study Results

No Results Posted as of Dec 14, 2020